# DeLLphi-301 (NCT05060016)

> A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05060016
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Amgen
- Conditions: Relapsed/Refractory Small Cell Lung Cancer
- Interventions: Tarlatamab
- Enrollment: 222
- Primary outcome: Part 1 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Investigator
- Primary outcome: Part 1 and Part 3 Only: Number of Participants who Experience One or More Treatment-emergent Adverse Events
- Primary outcome: Part 1 Only: Serum Concentrations of Tarlatamab
- Primary outcome: Part 1 and Part 2 Only: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 by Blinded Independent Central Review (BICR)

## Commentary we found

- X threads: 46
- YouTube: 38
- Podcasts: 25
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=dellphi-301-nct05060016

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05060016", "email": "<work email>"}; the inbox owner confirms by the emailed link.